Browsing "의학과" byAuthorYoon, Sung-Soo

Jump to:
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 20 to 29 of 29

Issue DateTitleAuthor(s)Type
2019Oncogenic effects of germline variants in lysosomal storage disease genes김형래Article
2020Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia문영철Article
2020Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)문영철Article
2012Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party성주명Meeting Abstract
2012Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis.문영철Meeting Abstract
2011Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis문영철Meeting Abstract
2007Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE (R), thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma: Interim results of phase II trial성주명Meeting Abstract
2016SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia김형래Article
2018The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma문영철Article
2020The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)문영철Article

BROWSE